SPEVIGO

This brand name is authorized in United States. It is also authorized in Austria, Croatia, Estonia, France, Italy, Japan, Lithuania, Romania, Spain.

Active ingredients

The drug SPEVIGO contains one active pharmaceutical ingredient (API):

1	Spesolimab UNII 5IB2J79MCX - SPESOLIMAB
	Spesolimab is a humanised antagonistic monoclonal immunoglobulin G1 (IgG1) antibody blocking human interleukin 36 receptor (IL36R) signalling. Binding of spesolimab to IL36R prevents the subsequent activation of IL36R by its ligands (IL36 α, β and γ) and downstream activation of pro-inflammatory pathways.
	Read more about Spesolimab

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
SPEVIGO Concentrate for solution for infusion	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
L04AC22		L Antineoplastic and immunomodulating agents → L04 Immunosuppressants → L04A Immunosuppressants → L04AC Interleukin inhibitors
Discover more medicines within L04AC22

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
EE	Ravimiamet	1896802
ES	Centro de información online de medicamentos de la AEMPS	1221688001
FR	Base de données publique des médicaments	68300246
IT	Agenzia del Farmaco	050464015
JP	医薬品医療機器総合機構	3999466A1026
LT	Valstybinė vaistų kontrolės tarnyba	1096136
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W69453001
US	FDA, National Drug Code	0597-0035